Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company focused on photodynamic therapy (PDT), has engaged Lytham Partners to lead its strategic investor relations and shareholder communication program. The company has recently completed several transformative actions, including restructuring its relationship with its former parent company, acquiring U.S. intellectual property and new drug applications, taking control of manufacturing, and securing $11 million in new funding.
Biofrontera commercializes Ameluz® with RhodoLED® lamp series for PDT treatment of actinic keratosis (AK), pre-cancerous skin lesions. The company is conducting clinical trials to expand product use for non-melanoma skin cancers and moderate to severe acne. Management expects to achieve meaningful profitability in the coming quarters.
Biofrontera Inc. (NASDAQ: BFRI), una società biofarmaceutica focalizzata sulla terapia fotodinamica (PDT), ha incaricato Lytham Partners di guidare le attività di relazioni con investitori strategiche e comunicazione agli azionisti. L'azienda ha recentemente completato diverse azioni trasformative, tra cui la ristrutturazione del rapporto con la sua ex società madre, l'acquisizione della proprietà intellettuale statunitense e delle nuove domande di farmaco, il controllo della produzione e l'ottenimento di 11 milioni di dollari in nuovi finanziamenti.
Biofrontera commercializza Ameluz® con la lampada RhodoLED® per la PDT nel trattamento della cheratosi attinica (AK), lesioni cutanee precancerose. L'azienda sta conducendo trial clinici per espandere l'uso del prodotto per i tumori cutanei non melanoma e per l'acne da moderata a severa. La direzione prevede di raggiungere una redditività significativa nei prossimi trimestri.
Biofrontera Inc. (NASDAQ: BFRI), una compañía biofarmacéutica centrada en la terapia fotodinámica (PDT), ha contratado a Lytham Partners para dirigir su programa estratégico de relaciones con inversores y comunicación con los accionistas. La compañía ha completado recientemente varias acciones transformadoras, entre ellas la reestructuración de su relación con su antigua empresa matriz, la adquisición de propiedad intelectual estadounidense y nuevas solicitudes de fármacos, el control de la fabricación y la obtención de 11 millones de dólares en nuevos financiamientos.
Biofrontera comercializa Ameluz® con la serie de lámparas RhodoLED® para el tratamiento PDT de la queratosis actínica (AK), lesiones cutáneas precancerosas. La empresa está llevando a cabo ensayos clínicos para ampliar el uso del producto para cánceres de piel no melanoma y para el acné de moderada a severa. La dirección espera una rentabilidad significativa en los próximos trimestres.
Biofrontera Inc. (NASDAQ: BFRI), PDT(광역치료) 분야에 초점을 맞춘 생물의약품 회사가 전략적 투자자 관계 및 주주 커뮤니케이션 프로그램을 주도하기 위해 Lytham Partners를 선임했습니다. 이 회사는 최근 전 모회사와의 관계 재구성, 미국 지적 재산권 및 신약 출원 취득, 제조 통제 확보, 그리고 1100만 달러의 신규 자금 조달 등 여러 변혁적 조치를 마무리했습니다.
Biofrontera는 Ameluz®와 RhodoLED® 램프 시리즈를 PDT 치료에 사용하여 광선 각화증(AK)으로 인한 피부 병변을 치료합니다. 이 회사는 피부 비멜란 종양 및 중등도에서 중증 여드름에 대한 사용 확대를 위한 임상 시험을 진행 중입니다. 경영진은 향후 분기에 의미 있는 수익성을 달성할 것으로 기대합니다.
Biofrontera Inc. (NASDAQ: BFRI), une société biopharmaceutique spécialisée dans la thérapie photodynamique (PDT), a confié à Lytham Partners la conduite de son programme stratégique de relations avec les investisseurs et de communication avec les actionnaires. La société a récemment accompli plusieurs actions transformatrices, notamment la réorganisation de sa relation avec son ancienne société mère, l'acquisition de propriétés intellectuelles américaines et de nouvelles demandes de médicaments, la prise de contrôle de la fabrication et la sécurisation de 11 millions de dollars de nouveaux financements.
Biofrontera commercialise Ameluz® avec la série de lampes RhodoLED® pour le traitement PDT de la kératose actinique (AK), des lésions cutanées précancéreuses. La société mène des essais cliniques pour étendre l'utilisation du produit pour les cancers de la peau non mélanocytaires et pour l'acné modérée à sévère. La direction prévoit d'atteindre une rentabilité significative au cours des prochains trimestres.
Biofrontera Inc. (NASDAQ: BFRI), ein biopharmazeutisches Unternehmen, das sich auf die fotodynamische Therapie (PDT) spezialisiert hat, hat Lytham Partners beauftragt, das strategische Investorenbeziehungs- und Aktionärskommunikationsprogramm zu leiten. Das Unternehmen hat kürzlich mehrere transformative Maßnahmen abgeschlossen, darunter die Restrukturierung des Verhältnisses zu seinem ehemaligen Mutterunternehmen, den Erwerb von US-Intellectual Property und neuen Arzneimittelanmeldungen, die Übernahme der Fertigung und die Sicherung von 11 Millionen US-Dollar an neuem Kapital.
Biofrontera vermarktet Ameluz® mit RhodoLED®-Lampenserie für die PDT-Behandlung von Aktinischer Keratose (AK), präkanzerösen Hautläsionen. Das Unternehmen führt klinische Studien durch, um die Produktanwendung auf nicht-melanomale Hautkrebsarten und moderat bis schweren Akne auszudehnen. Das Management erwartet in den kommenden Quartalen eine spürbare Rentabilität.
Biofrontera Inc. (NASDAQ: BFRI)، شركة أدوية حيوية مركزة على العلاج الضوئي الديناميكي (PDT)، قد تعاقدت مع Lytham Partners لقيادة برنامج علاقات المستثمرين الاستراتيجي واتصالات المساهمين. لقد أنجزت الشركة مؤخراً عدّة إجراءات تحويلية، بما في ذلك إعادة هيكلة علاقتها مع والدتها السابقة، والاستحواذ على الملكية الفكرية الأمريكية وطلبات أدوية جديدة، والسيطرة على التصنيع، وتأمين 11 مليون دولار من تمويلات جديدة.
تسوّق Biofrontera Ameluz® مع سلسلة RhodoLED® من المصابيح لاستخدام PDT في علاج التُكَيّسات الشمسية القِدَمية (AK)، والآفات الجلدية السابقة للسرطان. تقود الشركة تجارب سريرية لتوسيع استخدام المنتج لسرطانات الجلد غير الميلانينية وللحب الشباب من المتوسط إلى الشديد. وتتوقع الإدارة تحقيق ربحية ملموسة في الأرباع القادمة.
Biofrontera Inc. (NASDAQ: BFRI)，一家专注于光动力治疗（PDT）的生物制药公司，已任命 Lytham Partners 负责其战略投资者关系与股东沟通计划。该公司最近完成了若干具有变革性的行动，包括 与其前母公司关系的重组、美国知识产权及新药申请的收购、掌控制造以及获得1100万美元的新融资。
Biofrontera 将 Ameluz® 与 RhodoLED® 灯系列 商用于 PDT 治疗日光性角化病（AK）等皮肤前癌病变。公司正在开展临床试验，以扩大产品在非黑色素皮肤癌及中到重度痤疮的适用范围。管理层预计在未来几个季度实现显著盈利。
- Secured $11 million in new funding
- Management expects meaningful profitability in upcoming quarters
- Strategic acquisition of U.S. intellectual property and new drug applications
- Gained control of manufacturing operations
- Expanded product development pipeline for non-melanoma skin cancers and acne
- Dependency on licensors for product supply and obligations
- Potential supply chain disruption risks
- Uncertainty in clinical trial outcomes and regulatory approvals
WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program.
For more than 20 years, Lytham Partners has been one of the country's leading investor relations firms, having created one of the industry's largest and most diverse networks of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications. In addition to their relationships with many of the industry's most respected institutional investors, Lytham Partners has spent the past two decades creating an integrated platform that allows its clients far reaching exposure to investors in a consistent and in-depth format. This platform is matched with a communications and positioning approach that is streamlined throughout press releases, conference calls, investor presentations, corporate profiles, and websites.
Dr. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., commented, “Through a series of transformative actions, including restructuring our relationship with our former parent company, acquiring U.S. intellectual property and new drug applications, taking control of manufacturing, and securing
“Biofrontera has made tremendous progress in recent months, establishing a strong foundation to become a leading U.S. specialty dermatology company. By advancing innovative therapies that meet the needs of dermatology professionals and their patients, the Company is focused on expanding its market presence, enhancing its competitive position, and creating meaningful long-term value for shareholders,” said Ben Shamsian, Vice President of Lytham Partners. “We look forward to introducing Biofrontera to our platform of investors, while supporting best practices within their communications program at all levels to keep shareholders apprised of the exciting developments taking place at the Company."
To sign up for alerts on Biofrontera, please email or call Ben Shamsian at shamsian@lythampartners.com or 646-829-9701.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X .
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; whether the market opportunity for Ameluz® in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
What strategic changes has Biofrontera (BFRI) announced in September 2025?
What are Biofrontera's (BFRI) main products and treatment areas?
How much funding did Biofrontera (BFRI) secure in 2025?
What is Biofrontera's (BFRI) profitability outlook for 2025?
Who will handle Biofrontera's (BFRI) investor relations program?
